Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Prolonging tear film breakdown time" is not a specific molecule, receptor, or canonical therapeutic target. Instead, it refers to a **therapeutic goal** or *clinical endpoint* in ophthalmology—specifically the aim of increasing the stability and longevity of the precorneal tear film. The **tear break-up time** (TBUT) is a clinical measurement used to assess how long the tear film remains stable before breaking up after a blink[7]. A short TBUT indicates an unstable tear film and is associated with dry eye disease and related symptoms. The molecular basis of prolonging TBUT involves multiple components of the ocular surface system: - The **lipid layer**, produced by meibomian glands, reduces evaporation and stabilizes the air-tear interface[1]. - The **aqueous layer**, secreted by lacrimal glands, provides hydration and contains protective proteins[2][6]. - The **mucin layer**, especially membrane-associated mucins like MUC16 on corneal epithelial cells, ensures wettability and even distribution of tears across the cornea[1][3]. Therapies that "prolong TBUT" may include artificial tears containing lipids or mucinomimetics; prescription drugs such as diquafosol sodium or rebamipide that stimulate secretion of aqueous or mucin components; agents targeting neural regulation pathways like TRPM8 ion channels; regenerative approaches aimed at restoring gland function; or devices designed to stimulate natural tearing[3][4][6]. Because "prolonging tear film breakdown time" describes an outcome rather than a discrete molecular entity, it does not have standard aliases, abbreviations, molecular classifications beyond "other," nor direct interacting drugs. However, many therapies are developed with this endpoint in mind. In summary: This entry does not correspond to a single molecule/receptor but rather describes an important therapeutic objective in managing dry eye disease through various means that enhance one or more layers/components responsible for maintaining stable tears on the ocular surface[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Prolonging tear film breakdown time.